Glenmark Pharmaceuticals’ Generic of Leo Pharma’s Enstilar Approved


Glenmark Pharmaceuticals has achieved a significant milestone with the approval of its generic version of Leo Pharma’s Enstilar by regulatory authorities. Enstilar is a combination foam medication used to treat psoriasis, a chronic skin condition characterized by red, itchy, and scaly patches. In this blog post, we will explore the key points surrounding Glenmark Pharmaceuticals’ approval for the generic version of Enstilar, highlighting the implications for patients with psoriasis and the availability of cost-effective treatment options.

Key Points:

1. Glenmark Pharmaceuticals’ Generic Version of Enstilar:

Glenmark Pharmaceuticals has received regulatory approval for its generic version of Enstilar, a widely prescribed medication for the treatment of psoriasis. The generic version contains the same active ingredients as the brand-name product, with similar efficacy and safety profiles. Once launched in the market, Glenmark’s generic version of Enstilar will offer an affordable alternative for patients with psoriasis.

2. Increased Access and Affordability for Psoriasis Treatment:

The approval of Glenmark’s generic version of Enstilar is expected to increase access to cost-effective treatment options for patients with psoriasis. Psoriasis affects millions of people worldwide and can have a significant impact on their quality of life. However, many patients face challenges due to the high cost of branded medications. The availability of a generic alternative offers a more affordable option, potentially improving patient adherence to treatment regimens and overall outcomes.

3. Equivalency of Generic Version:

Approval of a generic medication requires demonstration of bioequivalence, meaning the generic version must show comparable absorption and effectiveness to the branded product. Glenmark Pharmaceuticals‘ generic version of Enstilar has undergone rigorous testing to ensure its equivalence to the original medication. Patients can have confidence in the safety and efficacy of the generic product, as it meets the same regulatory standards as the branded version.

4. Boosting Competition and Innovation:

The introduction of generic versions of medications promotes healthy competition in the pharmaceutical market. With multiple manufacturers producing a generic alternative for Enstilar, it will likely lead to competitive pricing, benefiting patients, insurers, and healthcare systems. Moreover, increased competition encourages innovation as manufacturers strive to develop more advanced and cost-effective formulations, ultimately improving treatment options and outcomes for patients with psoriasis.

5. Importance of Patient-Physician Discussion:

Patients with psoriasis considering the use of Glenmark Pharmaceuticals’ generic version of Enstilar should engage in open communication and consult with their physicians. Physicians, based on their professional judgment and knowledge of the patient’s medical history, can provide guidance on treatment options, including the use of generic medications. Collaborative discussions between patients and physicians are crucial for making informed decisions that prioritize both efficacy and affordability.

6. Future Prospects and Benefits:

The approval of Glenmark Pharmaceuticals’ generic version of Enstilar marks a significant step forward in improving access to affordable treatment options for patients with psoriasis. The availability of a generic alternative has the potential to alleviate financial burdens associated with the management of psoriasis, enabling patients to better adhere to their treatment regimens. As more generic options become available, the market will continue to evolve, fostering competition and driving innovation in psoriasis management.


Glenmark Pharmaceuticals‘ approval of the generic version of Leo Pharma’s Enstilar represents a positive development in the treatment of psoriasis. The availability of a cost-effective alternative will increase access to treatment, improving patient outcomes and quality of life. The approval also highlights the importance of competition in the pharmaceutical market, leading to increased innovation and affordable treatment options. Patients with psoriasis should engage in open discussions with their healthcare providers to make informed decisions about treatment options, including the use of generic medications. With the introduction of generic alternatives, the future holds promise for improved psoriasis management and better outcomes for patients.